Denosumab versus romosozumab for postmenopausal osteoporosis treatment

Abstract Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular-targeted drugs for postmenopausal osteoporosis treatment. However, no studies have directly compared their therapeutic effects or safety in postmenopausal osteoporosis. This retrospective obser...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tomonori Kobayakawa, Akiko Miyazaki, Makoto Saito, Takako Suzuki, Jun Takahashi, Yukio Nakamura
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/1b85915e4614449ba0b1d9cc85b515ff
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!